Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial
Background: Dengue is the most significant mosquito-borne viral disease; there are no specific therapeutics. The antiparasitic drug ivermectin efficiently inhibits the replication of all 4 dengue virus serotypes in vitro. Methods: We conducted 2 consecutive randomized, double-blind, placebo-controll...
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2022
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/78200 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.78200 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.782002022-08-04T16:24:01Z Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial Yupin Suputtamongkol Panisadee Avirutnan Dumrong Mairiang Nasikarn Angkasekwinai Kannika Niwattayakul Eakkawit Yamasmith Fadhil A.Hamad Saleh-Arong Adisak Songjaeng Tanapan Prommool Nattaya Tangthawornchaikul Chunya Puttikhunt Saowalak Hunnangkul Chulaluk Komoltri Suwich Thammapalo Prida Malasit Siriraj Hospital Thailand Ministry of Public Health Thailand National Center for Genetic Engineering and Biotechnology Muang Loei Ram Hospital Medicine Background: Dengue is the most significant mosquito-borne viral disease; there are no specific therapeutics. The antiparasitic drug ivermectin efficiently inhibits the replication of all 4 dengue virus serotypes in vitro. Methods: We conducted 2 consecutive randomized, double-blind, placebo-controlled trials in adult dengue patients to evaluate safety and virological and clinical efficacies of ivermectin. After a phase 2 trial with 2 or 3 days of 1 daily dose of 400 µg/kg ivermectin, we continued with a phase 3, placebo-controlled trial with 3 days of 400 µg/kg ivermectin. Results: The phase 2 trial showed a trend in reduction of plasma nonstructural protein 1 (NS1) clearance time in the 3-day ivermectin group compared with placebo. Combining phase 2 and 3 trials, 203 patients were included in the intention to treat analysis (100 and 103 patients receiving ivermectin and placebo, respectively). Dengue hemorrhagic fever occurred in 24 (24.0%) of ivermectin-treated patients and 32 (31.1%) patients receiving placebo (P =. 260). The median (95% confidence interval [CI]) clearance time of NS1 antigenemia was shorter in the ivermectin group (71.5 [95% CI 59.9-84.0] hours vs 95.8 [95% CI 83.9-120.0] hours, P =. 014). At discharge, 72.0% and 47.6% of patients in the ivermectin and placebo groups, respectively had undetectable plasma NS1 (P =. 001). There were no differences in the viremia clearance time and incidence of adverse events between the 2 groups. Conclusions: A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen. 2022-08-04T09:24:01Z 2022-08-04T09:24:01Z 2021-05-15 Article Clinical Infectious Diseases. Vol.72, No.10 (2021), E586-E593 10.1093/cid/ciaa1332 15376591 10584838 2-s2.0-85107082221 https://repository.li.mahidol.ac.th/handle/123456789/78200 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85107082221&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Yupin Suputtamongkol Panisadee Avirutnan Dumrong Mairiang Nasikarn Angkasekwinai Kannika Niwattayakul Eakkawit Yamasmith Fadhil A.Hamad Saleh-Arong Adisak Songjaeng Tanapan Prommool Nattaya Tangthawornchaikul Chunya Puttikhunt Saowalak Hunnangkul Chulaluk Komoltri Suwich Thammapalo Prida Malasit Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
description |
Background: Dengue is the most significant mosquito-borne viral disease; there are no specific therapeutics. The antiparasitic drug ivermectin efficiently inhibits the replication of all 4 dengue virus serotypes in vitro. Methods: We conducted 2 consecutive randomized, double-blind, placebo-controlled trials in adult dengue patients to evaluate safety and virological and clinical efficacies of ivermectin. After a phase 2 trial with 2 or 3 days of 1 daily dose of 400 µg/kg ivermectin, we continued with a phase 3, placebo-controlled trial with 3 days of 400 µg/kg ivermectin. Results: The phase 2 trial showed a trend in reduction of plasma nonstructural protein 1 (NS1) clearance time in the 3-day ivermectin group compared with placebo. Combining phase 2 and 3 trials, 203 patients were included in the intention to treat analysis (100 and 103 patients receiving ivermectin and placebo, respectively). Dengue hemorrhagic fever occurred in 24 (24.0%) of ivermectin-treated patients and 32 (31.1%) patients receiving placebo (P =. 260). The median (95% confidence interval [CI]) clearance time of NS1 antigenemia was shorter in the ivermectin group (71.5 [95% CI 59.9-84.0] hours vs 95.8 [95% CI 83.9-120.0] hours, P =. 014). At discharge, 72.0% and 47.6% of patients in the ivermectin and placebo groups, respectively had undetectable plasma NS1 (P =. 001). There were no differences in the viremia clearance time and incidence of adverse events between the 2 groups. Conclusions: A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen. |
author2 |
Siriraj Hospital |
author_facet |
Siriraj Hospital Yupin Suputtamongkol Panisadee Avirutnan Dumrong Mairiang Nasikarn Angkasekwinai Kannika Niwattayakul Eakkawit Yamasmith Fadhil A.Hamad Saleh-Arong Adisak Songjaeng Tanapan Prommool Nattaya Tangthawornchaikul Chunya Puttikhunt Saowalak Hunnangkul Chulaluk Komoltri Suwich Thammapalo Prida Malasit |
format |
Article |
author |
Yupin Suputtamongkol Panisadee Avirutnan Dumrong Mairiang Nasikarn Angkasekwinai Kannika Niwattayakul Eakkawit Yamasmith Fadhil A.Hamad Saleh-Arong Adisak Songjaeng Tanapan Prommool Nattaya Tangthawornchaikul Chunya Puttikhunt Saowalak Hunnangkul Chulaluk Komoltri Suwich Thammapalo Prida Malasit |
author_sort |
Yupin Suputtamongkol |
title |
Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
title_short |
Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
title_full |
Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
title_fullStr |
Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
title_full_unstemmed |
Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
title_sort |
ivermectin accelerates circulating nonstructural protein 1 (ns1) clearance in adult dengue patients: a combined phase 2/3 randomized double-blinded placebo controlled trial |
publishDate |
2022 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/78200 |
_version_ |
1763492004914790400 |